Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations.
about
Challenge of changing nursing home prescribing cultureAtypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review.Results of a longitudinal analysis of national data to examine relationships between organizational and market characteristics and changes in antipsychotic prescribing in US nursing homes from 1996 through 2006.Automated pharmacy databases and behavioral health care quality assurance.Variation in psychotropic drug use in nursing homes.Impact of legislation on nursing home care in the United States: lessons for the United KingdomTrends in treatment with antipsychotic medication in relation to national directives, in people with dementia - a review of the Swedish contextAntipsychotic use among nursing home residentsBroadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.Regulation and mindful resident care in nursing homes.An electronic health record driven algorithm to identify incident antidepressant medication users.State regulatory enforcement and nursing home termination from the medicare and medicaid programs.The effectiveness of quality systems in nursing homes: a reviewPressure ulcer prevalence in long-term nursing home residents since the implementation of OBRA '87. Omnibus Budget Reconciliation Act.Evaluation of clinical practice guidelinesRelapse risk after discontinuation of risperidone in Alzheimer's disease.A Review Exploring the Relationship Between Nursing Home Staffing and Antipsychotic Medication Use.The effect of pay-for-performance in nursing homes: evidence from state Medicaid programsUse of physical restraints and antipsychotic medications in nursing homes: a cross-national study.Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia.Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilitiesState "technical assistance programs" for nursing home quality improvement: variations and potential implications.Impact of public reporting on quality of postacute care.The intended and unintended consequences of benzodiazepine monitoring programmes: a review of the literature.An Evaluation of Performance Thresholds in Nursing Home Pay-for-Performance.Psychotropic use among older residents of board and care facilities.Informed Family Member Involvement to Improve the Quality of Dementia Care in Nursing Homes.Predictors of antipsychotic withdrawal or dose reduction in a randomized controlled trial of provider education.Alcohol and drug misuse in the nursing home.Pharmacologic treatment of agitation in dementia: a comprehensive review.Psychiatric assessments of nursing home residents under OBRA-87: should PASARR be reformed? Pre-Admission Screening and Annual Review.Use of antipsychotic drugs in nursing homes: current compliance with OBRA regulations.Antipsychotic Use in Dementia.Response to regulatory stringency: the case of antipsychotic medication use in nursing homes.Developing rehabilitative behavioral interventions for long-term care: technology transfer, acceptance, and maintenance issues.Second-generation antipsychotic drug use in hospital inpatients with dementia: the impact of a safety warning on rates of prescribing.[A qualitative exploration of the chronic use of psychotropic drugs in nursing homes].The impact of legislation on psychotropic drug use in nursing homes: a cross-national perspective.Compliance with PASARR recommendations for Medicaid recipients in nursing homes. Preadmission Screening and Annual Resident Review.Identifying patterns of disruptive behavior in long-term care residents.
P2860
Q26865397-F183ADB8-4A5D-43F6-83A5-0A656CED445EQ33203719-15DAAF3F-0907-4866-BAB4-2FE8F410B9F1Q33483929-191324B6-9F23-467C-BF89-1DBD3A1A76C8Q33583198-4AEC8CD0-94EB-4697-8AB8-54F5CE80E209Q33583695-89D01B26-EFB7-4E2C-95EF-FC554FB5180DQ33798248-85185E7D-01CA-4F77-822C-61427F79C94FQ33910629-EEE8F6BC-736B-46A7-8FE6-295B7E74E39CQ33924005-0FE4C1F0-102E-4177-9424-9BDA506AD747Q33960193-39BA039D-6257-48AA-B827-F3ADED6D80F6Q34054412-3B009AE4-5201-45CB-8829-ED9193934FEFQ34100018-3DC03486-10E2-4D59-A8B6-A9F1FF01EF09Q34293168-71C98169-C6BD-47ED-9EFD-95E8AECEACCAQ34462964-6BBFC603-C4AD-49FB-9BEE-84324F2B98CFQ34619269-03BB0BA6-85D7-406F-9F22-10B4C65E0D79Q34712849-E0ABD510-704B-45FE-9500-C2CED7900685Q36375421-ECB51AA1-59E9-4242-8E83-89C6B4BDAD06Q36389719-E91F94C5-9BF7-41A1-B825-DB18D2B6C78FQ36854193-5F4F22DB-9F07-4699-BEA2-A039E58D2E38Q37150471-77877A7F-C520-4384-AD6A-549E66FC2B48Q37166113-68214109-E38F-457B-8DA5-E54F3AC8551AQ37172915-996F4006-B1F0-42C8-8D0A-FAFEB51F3F6BQ37201977-07DBD18A-02B1-4210-BD05-CB7E0A479EB8Q37335696-23A5DFEA-9130-464C-BFBE-13038443139FQ37844624-364DC793-E89F-486E-93A6-9E2702F95598Q39955447-E51E8EA2-7CE9-4940-9F33-9B164DF09B9DQ40376974-A3FF7D00-BF9B-4C5C-83A7-315BEB954899Q40611802-262F464C-E631-4832-ABBD-DC4CAF2EBE3AQ40906260-08FFE9CD-9AA7-4F2C-A18D-151AFE27F59FQ41073350-29E081EF-DCA7-48A5-8A98-9285077DB1C1Q41169288-6CD23E9F-BFD5-42E3-9E5A-2B62095834DAQ41610924-32DCD69A-7C8C-4550-A8A0-58FD9514C9F0Q41706818-6FC6B8CB-5E8E-46A9-8021-B554E545846CQ41827089-02228407-ADCF-4EB9-BD0C-6887ED58CDD0Q44804861-44A63110-C1F3-464C-8131-B03F1A6B15D0Q45959538-81B4E084-E5D4-43B9-A548-2B3B7894ACC2Q46100895-42E2DC7C-E188-49D7-BADC-A48E16BD3B52Q49167702-EB3DF026-4AA8-4A3A-8930-8E6CB1037DB2Q50133493-8EC8934A-AB7A-47FB-B651-0E66464332DDQ50634098-970E4EAF-D41D-40E0-BA25-F932A45D9252Q51983248-53CE2702-594B-4A98-8FD4-7B55BCE9F104
P2860
Changes in antipsychotic drug use in nursing homes during implementation of the OBRA-87 regulations.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Changes in antipsychotic drug ...... on of the OBRA-87 regulations.
@en
type
label
Changes in antipsychotic drug ...... on of the OBRA-87 regulations.
@en
prefLabel
Changes in antipsychotic drug ...... on of the OBRA-87 regulations.
@en
P2093
P1476
Changes in antipsychotic drug ...... on of the OBRA-87 regulations.
@en
P2093
P304
P356
10.1001/JAMA.1994.03510290040034
P407
P577
1994-02-01T00:00:00Z